1
Stéphane De Lombaert
BARTOLOZZI Alessandra, BOSANAC Todd, CHEN Zhidong, DE LOMBAERT Stéphane, HUBER John D, LIU Weimin, LO Ho Yin, LOKE Pui Leng, RIETHER Doris, TYE Heather, WU Lifen, ZINDELL Renee M: INHIBITEURS OXADIAZOLE DE PRODUCTION DE LEUCOTRIÈNES, OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION. BOEHRINGER INGELHEIM INTERNATIONAL, BARTOLOZZI Alessandra, BOSANAC Todd, CHEN Zhidong, DE LOMBAERT Stéphane, HUBER John D, LIU Weimin, LO Ho Yin, LOKE Pui Leng, RIETHER Doris, TYE Heather, WU Lifen, ZINDELL Renee M, MORRIS Michael P, March 29, 2012: WO/2012/040137

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases an ...


2

3
Bosanac Todd, Ginn John David, Hickey Eugene Richard, Kirrane Thomas Martin, Liu Weimin, Prokopowicz Anthony S, Shih Cheng Kon, Snow Roger John, Turner Michael Robert, Wu Frank, Young Erick Richard, Schlyer Sabine K: Rho kinase inhibitors. Boehringer Ingelheim International, Boehringer Ingelheim Pharma & Co Kg, Bosanac Todd, Ginn John David, Hickey Eugene Richard, Kirrane Thomas Martin, Liu Weimin, Prokopowicz Anthony S, Shih Cheng Kon, Snow Roger John, Turner Michael Robert, Wu Frank, Young Erick Richard, Schlyer Sabine K, MORRIS Michael P, March 27, 2008: WO/2008/036540 (21 worldwide citation)

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compos ...


4

5

6

7
BOSANAC TODD, GINN JOHN DAVID, HICKEY EUGENE RICHARD, KIRRANE THOMAS MARTIN JR, LIU WEIMIN, PROKOPOWICZ ANTHONY S, SCHLYER SABINE K, SHIH CHENG KON, SNOW ROGER JOHN, TURNER MICHAEL ROBERT, WU FRANK, YOUNG ERICK RICHARD: Inhibiteurs de la RHO-kinase, RHO-Kinase-Hemmer, RHO kinase inhibitors. AERIE PHARMACEUTICALS, November 28, 2012: EP2526948-A1

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-isoquinolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compo ...


8
Bosanac Todd, Ginn John David, Hickey Eugene Richard, Kirrane Thomas Martin, Liu Weimin, Prokopowicz Anthony S, Shih Cheng Kon, Snow Roger John, Turner Michael Robert, Wu Frank, Young Erick Richard, Schlyer Sabine K: Rho kinase inhibitors. Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, June 17, 2009: EP2068878-A2

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compos ...


9

10
BERRY Angela, BOSANAC Todd, GINN John David, HOPKINS Tamara Denise, SCHLYER Sabine, SOLEYMANZADEH Fariba, WESTBROOK John, YU Maolin, ZHANG Zhonghua: [fr] ACTIVATEURS DE GUANYLATE CYCLASE SOLUBLE, [en] SOLUBLE GUANYLATE CYCLASE ACTIVATORS. BERRY Angela, BOSANAC Todd, GINN John David, HOPKINS Tamara Denise, SCHLYER Sabine, SOLEYMANZADEH Fariba, WESTBROOK John, YU Maolin, ZHANG Zhonghua, BOEHRINGER INGELHEIM INTERNATIONAL, MORRIS Michael P, February 21, 2013: WO/2013/025425

[en] The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 - R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of vario ...